Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Results of Operations and Financial Condition

Voyager Therapeutics,Inc. (NASDAQ:VYGR) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On May 9, 2017, Voyager Therapeutics, Inc. (the Company)
announced financial results for the quarter ended March 31, 2017.
The full text of the press release issued in connection with the
announcement is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d)Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:

Mar

Exhibit No.

Description

99.1

Press release dated May 9, 2017 entitled Voyager
Therapeutics Reports First Quarter 2017 Financial Results
and Corporate Highlights

2


About Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Recent Trading Information

Voyager Therapeutics, Inc. (NASDAQ:VYGR) closed its last trading session down -0.04 at 8.97 with 107,422 shares trading hands.

An ad to help with our costs